167 related articles for article (PubMed ID: 19492871)
1. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing.
Peyrl A; Sauermann R; Chocholous M; Azizi AA; Jäger W; Höferl M; Slavc I
Clin Pharmacokinet; 2014 Feb; 53(2):165-73. PubMed ID: 24129691
[TBL] [Abstract][Full Text] [Related]
3. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
Phuphanich S; Maria B; Braeckman R; Chamberlain M
J Neurooncol; 2007 Jan; 81(2):201-8. PubMed ID: 16941075
[TBL] [Abstract][Full Text] [Related]
6. Liposomal cytarabine for central nervous system embryonal tumors in children and young adults.
Partap S; Murphy PA; Vogel H; Barnes PD; Edwards MS; Fisher PG
J Neurooncol; 2011 Jul; 103(3):561-6. PubMed ID: 20859651
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors.
Lassaletta A; Lopez-Ibor B; Mateos E; Gonzalez-Vicent M; Perez-Martinez A; Sevilla J; Diaz MA; Madero L
J Neurooncol; 2009 Oct; 95(1):65-69. PubMed ID: 19381444
[TBL] [Abstract][Full Text] [Related]
8. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.
Rueda Domínguez A; Olmos Hidalgo D; Viciana Garrido R; Torres Sánchez E
Clin Transl Oncol; 2005 Jul; 7(6):232-8. PubMed ID: 16131445
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine.
Bohn JP; Reinstadler V; Pall G; Stockhammer G; Steurer M; Oberacher H; Wolf D
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):845-851. PubMed ID: 31435852
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series.
Chamberlain MC
J Neurooncol; 2012 Aug; 109(1):143-8. PubMed ID: 22539243
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.
Angst MS; Drover DR
Clin Pharmacokinet; 2006; 45(12):1153-76. PubMed ID: 17112293
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.
Jaeckle KA; Phuphanich S; Bent MJ; Aiken R; Batchelor T; Campbell T; Fulton D; Gilbert M; Heros D; Rogers L; O'Day SJ; Akerley W; Allen J; Baidas S; Gertler SZ; Greenberg HS; LaFollette S; Lesser G; Mason W; Recht L; Wong E; Chamberlain MC; Cohn A; Glantz MJ; Gutheil JC; Maria B; Moots P; New P; Russell C; Shapiro W; Swinnen L; Howell SB
Br J Cancer; 2001 Jan; 84(2):157-63. PubMed ID: 11161370
[TBL] [Abstract][Full Text] [Related]
15. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma.
Gállego Pérez-Larraya J; Palma JA; Carmona-Iragui M; Fernández-Torrón R; Irimia P; Rodríguez-Otero P; Panizo C; Martínez-Vila E
J Neurooncol; 2011 Jul; 103(3):603-9. PubMed ID: 20953897
[TBL] [Abstract][Full Text] [Related]
16. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C
Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
[TBL] [Abstract][Full Text] [Related]
17. Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma.
Ostermann K; Pels H; Kowoll A; Kuhnhenn J; Schlegel U
J Neurooncol; 2011 Jul; 103(3):635-40. PubMed ID: 20953896
[TBL] [Abstract][Full Text] [Related]
18. [Cerebrospinal fluid examination after liposomal cytarabine intrathecal injection].
Guillaume C; Vegas H; Pastuszka A; Le Brun C; Lanotte P
Ann Biol Clin (Paris); 2018 Oct; 76(5):568-570. PubMed ID: 30154068
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
Bassan R; Masciulli A; Intermesoli T; Audisio E; Rossi G; Pogliani EM; Cassibba V; Mattei D; Romani C; Cortelezzi A; Corti C; Scattolin AM; Spinelli O; Tosi M; Parolini M; Marmont F; Borlenghi E; Fumagalli M; Cortelazzo S; Gallamini A; Marfisi RM; Oldani E; Rambaldi A
Haematologica; 2015 Jun; 100(6):786-93. PubMed ID: 25749825
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]